Drugs / Matricaria recutita
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT06859476 | May → Sep 2025 | — | Laboratorios Sophia S.A de C.V. | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT06373653 Comparator | Feb 2025 | asthenopia | Laboratorios Sophia S.A de C.V. | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Matricaria recutita | “Matricaria recutita 0.025%. One drop four times per day (QID), with a minimun interval of 3 hours between administrations, for 7 days.” NCT06859476 ↗1“Matricaria recutita 0.025%, Ophthalmic solution.” NCT06373653 ↗ |
| Route | Topical | “Topical ophthalmic” NCT06373653 ↗ |